Ixico Regulatory News (IXI)

12 May 2005 16:59

Phytopharm PLC12 May 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) NAME OF COMPANY PHYTOPHARM PLC 2) NAME OF DIRECTOR DR R P DIXEY 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of an non-beneficial interest AS 2 ABOVE 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them. (If notified) AS 2 ABOVE 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) AS 2 ABOVE 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary GRANT OF SHARE OPTIONS UNDER THE PHYTOPHARM PERFORMANCE SHARE PLAN 2003 7) Number of shares/amount of stock acquired 8) Percentage of issued Class 9) Number of shares/amount of stock disposed 10) Percentage of issued Class(any treasury shares held by company should not be taken into account when calculating percentage) 11) Class of security 12) Price per share 13) Date of transaction 14) Date company informed 15) Total holding following this notification 16) Total percentage holding of issued class following this notification IF A DIRECTOR HAS BEEN GRANTED OPTIONS BY THE COMPANY PLEASE COMPLETE THE FOLLOWING BOXES 17) Date of grant 11 MAY 2005 18) Period during which or date on which exercisable 11 MAY 2008 TO 10 MAY 2015 SUBJECT TO PERFORMANCE CRITERIA 19) Total amount paid (if any) for grant of the option NIL 20) Description of shares or debentures involved: class, number. 23,055 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 125.5 PENCE 22) Total number of shares or debentures over which options held following this notification 406,064 23) Any additional information PERFORMANCE CRITERIA ARE BASED ON TOTAL SHAREHOLDERRETURN COMPARED TO COMPARATOR GROUPS ON THE THIRDANNIVERSARY OF GRANT. NO OPTIONS VEST FOR BELOW MEDIANPERFORMANCE, 25% VEST FOR MEDIAN PERFORMANCE AND 100% VESTFOR UPPER DECILE AND ABOVE WITH PRORATE VESTING BETWEEN MEDIANAND UPPER DECILE PERFORMANCE. FOR 15,370 OPTIONS THE COMPARATOR GROUPCOMPRISES 27 OTHER UK LISTED BIOTECH COMPANIES, AND FOR 7,685OPTIONS THE COMPARATOR GROUP IS THE FTSE SMALL CAP INDEX. 24) Name of contact and telephone number for queries 25) Name and signature of authorised company official responsible for making this notification DR G W CHONG Date of Notification 12 MAY 2005 This information is provided by RNS The company news service from the London Stock Exchange